Joshua Fitch, Senior Editor

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Liz Miracle, PT, MPT, WCS, discusses a retrospective analysis of 4,662 patients finding comparable pelvic health outcomes across virtual, hybrid, and in-person care.

Damian Alagia, III, MD, attributes gaps in prenatal STI detection and treatment to systemic flaws in access rather than individual clinical judgment.

A University of Michigan pilot study, discussed here by lead researcher Alex F. Peahl, MD, MSc, found patient-operated remote ultrasonography feasible for completing biophysical profiles in high-risk pregnancies.

Michael A. Reed, MD, MSCP, outlines immediate, practical steps physicians can take to address women's sexual health in their current roles.

Jeffrey Jensen, MD, MPH, explains the Gwyn Lo patch's Pearl Index following its recent FDA approval.

Michael A. Reed, MD, MSCP, explains how a structured framework for women's sexual health can address fragmentation and legitimize concerns often dismissed in routine care.

Jeffrey Jensen, MD, MPH, welcomes the newly approved Gwyn Lo contraceptive patch as an expanded, low-estrogen option for patients seeking a once-weekly method.

A curated look at the most engaging expert interviews from Contemporary OB/GYN in July 2026, highlighting clinician perspectives on endometriosis, perinatal mental health, menopause, and emerging therapeutic insights.

As we close out July, take a look back at key women's health FDA and other regulatory updates from the month.

Joy Baker, MD, FACOG, explains how zuranolone's rapid onset gives clinicians a meaningfully different counseling conversation for PPD.

BV-positive women had higher STI coinfection rates than BV-negative women in a study from Quest Diagnostics and Hologic, Inc.

Spring Fertility launched the Personalized IVF Calculator built on 2M+ data points from 25,000+ cycles.

FDA approved norelgestromin and ethinyl estradiol (Gwyn Lo; Viatris) as a low-dose once-weekly contraceptive patch.

A cohort study of 15,382 mother-infant dyads found that subfecundity was independently associated with elevated autism spectrum disorder odds and behavioral problem scores in offspring, while IVF treatment showed no significant neurodevelopmental associations.

Corresponding author Cynthia Gyamfi-Bannerman, MD, MS, says late preterm hypoglycemia did not adversely affect neurodevelopment.

Natural Cycles received a sixth FDA clearance for an updated version of its fertility-tracking algorithm.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

ACOG warns that CMS’ proposed G-codes for 2027 would create a dual maternity billing system, worsening disparities while increasing confusion.

Roche's cobas BV/CV assay received FDA clearance as a single-swab test for bacterial vaginosis and candida vaginitis.

New York’s Safe Motherhood Initiative bundle coincided with drops in SMM, DIC, and hysterectomy after postpartum hemorrhage.

Connor Frey, MD, explains why semaglutide and tirzepatide, but not liraglutide, generated menstrual adverse event signals in a FAERS pharmacovigilance analysis.

Semaglutide showed broad menstrual adverse event signals in a FAERS analysis of reproductive-aged patients.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

CDC data show 15.2% of US pregnant women reported current alcohol use in 2021-2024, up from 13.5% in 2018-2020.

ACOG, SWHR, and WFRC are calling on Congress to invest $20B over 10 years to close the women's health gap.

IGFBP4/SHBG screen-guided care cut NICU admissions from 16.4% to 12.8% in nulliparous PRIME trial participants.

One in 3 US women aged 35 and older is unsure if they’re in perimenopause, driven by symptom confusion and care barriers.

Alcohol use increased from 8% to 44% postpartum among pregnant people with HIV, with distinct risk factors identified for alcohol vs cannabis use.

A pilot trial found nicotinamide riboside and pterostilbene cut hot flashes, bloating, and poor sleep by 50% or more in 7 days.